1 / 1

Limited Efficacy of Low-Dose Rapamycin in Ad-Flt3L + Ad-TK/GCV Immunotherapy

Supplementary figure illustrating the lack of enhancement with low-dose Rapamycin (150 µg/kg/day) in Ad-Flt3L + Ad-TK/GCV immunotherapy at day 0.5 to 12.

caldwell-mcclain
Download Presentation

Limited Efficacy of Low-Dose Rapamycin in Ad-Flt3L + Ad-TK/GCV Immunotherapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RG2 Ad-Flt3L/TK Rapamycin (150µg/kg/day) 40 GCV d 0 5 12 Supplementary figure 5:Low dose Rapamycin does not enhance Ad-Flt3L + Ad-TK/GCV immunotherapy a b

More Related